Everything I say is in my opinion, do your own DD and make your decision wisely! Don't spend more then you can afford to lose, OTC's are Cruel at Best
Followers | 1066 |
Posts | 135,765 |
Boards Moderated | 0 |
Alias Born | 08/25/2010 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$OTLC .14 Going $1 Billion - $2 Billion IPO
$OTLC .14 Going $1 Billion - $2 Billion IPO
Steven W. King
Steven W. King served as the CEO of Peregrine Pharmaceuticals, Inc. (Nasdaq: CDMO) and its wholly-owned biomanufacturing subsidiary Avid Bioservices, Inc., for over 15 years, during which time the company advanced its lead compound through Phase 3 development, while growing revenues to over $55 million. Prior to joining Peregrine, Mr. King was employed at Vascular Targeting Technologies, Inc., which was acquired by Peregrine in 1997. Mr. King served in a variety of executive roles at Peregrine, including Director of Research and Development (1997 to 2000), Vice President Technology and Product development (2000 to 2002), Chief Operating officer (2002 to 2003) and Chief Executive Officer (2003 to 2017). Mr. King served on the Board of Directors of Peregrine from 2003 until 2017. Mr. King previously worked at the University of Texas Southwestern Medical Center and is co-inventor on over 40 U.S. and foreign patents and patent applications in the vascular targeting agent field. Mr. King received his Bachelor's and Master's degrees from Texas Tech University in Cell and Molecular Biology.
Anthony Maida, III
Most recently, Dr. Maida was vice president of clinical research and general manager of oncology, worldwide, for a leading international contract research organization. He has served as president and CEO of both Replicon NeuroTherapeutics, Inc. and Jenner Therapies, interim CEO for Trellis Bioscience, Inc., and president of CancerVax Corporation, where he secured the Company?s first financing of $30 million. Today, Dr. Maida serves as a senior advisor for multiple investment firms and life science companies. He also sits on the board of directors of Spectrum Pharmaceuticals, Inc.
Saran Saund CBO >>
Silicon Valley entrepreneur, Saran has been founder, CEO and GM at startups and public companies. Passionate about applying technology innovations to real world markets, he successfully founded an AI consortium to accelerate enterprise adoption of AI which engaged leading universities and technology vendors. A startup veteran, his track record includes senior leadership roles at companies that were acquired by leaders such as Marvell (MRVL) and Qualcomm (QCOM). His startup Cybercash (CYCH) had a successful IPO on NASDAQ. Saran started his career at Xerox PARC pushing 1�s and 0�s as a software engineer.
Seymour Fein Chief Med. Officer >>
Dr. Fein's professional activities have been focused on drug development research for over 35 years. He has been extensively involved in the successful development of numerous drugs, biologics and medical devices over this time leading to FDA approvals for over 20 drugs (NDAs, sNDAs, BLAs) and devices (PMAs). Dr. Fein was also the medical director of Bayer Healthcare Pharmaceuticals (U.S.) where he was responsible for therapeutic areas including gastroenterology, oncology, and cardiology. He later served as medical director for Rorer Group (now part of Sanofi) and Ohmeda (now part of Baxter). Dr. Fein founded and has been managing partner of a clinical and regulatory consulting organization and has worked closely with the Division of Gastroenterology and Inborn Errors Products at the FDA. He has participated in the development of and FDA approval of numerous drug products in many therapeutic areas. Dr. Fein has successfully overseen entrepreneurial drug development leading to the FDA approval of two orphan drug products in the field of gastroenterology. Dr. Fein received his B.A. degree from the University of Pennsylvania and his M.D. degree with honors from New York Medical College. Dr. Fein is board-certified in both oncology and internal medicine.
Amit Bhupendra Shah CFO >>
Amit Shah, age 53, has served as a senior financial officer for a number of life science companies, including Chief Financial Officer at Marina Biotech, Inc., a publicly traded biotechnology company (2017 to 2018); Vice President of Finance & Accounting and Acting Chief Financial Officer at Insightra Medical Inc. (2014 to 2015); VP Finance and Acting Chief Financial Officer at IgDraSol Inc. (2013); Corporate Controller & Director of Finance at ISTA Pharmaceuticals (2010 to 2012); Corporate Controller at Spectrum Pharmaceuticals (2007 to 2010): and as Controller / Senior Manager Internal Audits at Caraco Pharmaceuticals Laboratories (2000 to 2007). In addition to his work with life sciences companies, Mr. Shah served as the Chief Financial Officer at Eagle Business Performance Services, a management consulting and business advisory firm (2018 through March 2019) and as a consultant and ultimately Senior Director of Finance -- ERP, at Young's Market Company (2015 to 2017). Mr. Shah received a Bachelor's of Commerce degree from the University of Mumbai, and is an Associate Chartered Accountant from The Institute of Chartered Accountants of India. Mr. Shah is also an inactive CPA from Colorado, USA.
Vuong Trieu CEO >>
Vuong Trieu, Ph.D., has been involved in drug discovery, development and commercialization for over 25 years, including his contributions as co-inventor of Abraxane. He has served as Chairman and Chief Executive Officer of Oncotelic, Inc. since its formation in 2015. He previously served as Executive Chairman and Interim CEO of Marina Biotech, Inc. from 2016 to 2018. He also served as President and CEO of IgDraSol, Inc. beginning in 2012 until its acquisition by Sorrento Therapeutics, Inc. in 2013. He served as Chief Scientific Officer for Sorrento Therapeutics, Inc. and a member of that company's board of directors from 2013 until 2014. Previously, Dr. Trieu was Sr. Director of Pharmacology/Biology at Abraxis Bioscience/Celgene. Previously, Dr. Trieu held positions at Genetic Therapy/Sandoz, Applied Molecular Evolution/Lily and Parker Hughes Institute. Dr. Trieu holds a PhD in Microbiology, BS in Microbiology and Botany. Dr. Trieu has over 100 patent applications and 39 issued US patents.
The founding team members of Oncotelic were responsible for the development of Celgene’s Abraxane as a chemotherapeutic agent for breast, lung, melanoma, and pancreatic cancer. Abraxane was approved in 2005 and has more than $1B in sales annually. The same team was also responsible for the development of Cynviloq, a next generation Abraxane, which was acquired by NantPharma for $1.3B. Mateon/Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on pediatric cancer patients. For more information, please visit www.oncotelic.com and www.mateon.com.
$OTLC .14 Huge Gem IPO Target $2.60 to $5.20
$OTLC .14 Huge Gem IPO Target $2.60 to $5.20
$OTLC .14 Huge Late Stage acquisition of AL-101, expands Oncotelic's product portfolio to the fast to market 505(b)2 regulatory pathway. AL-101 has many of the same properties necessary to replicate the successes I had with the 505(b)2 route for Abraxane at Abraxis and Cynviloq at Igdrasol
$OTLC .14 Huge Late Stage acquisition of AL-101, expands Oncotelic's product portfolio to the fast to market 505(b)2 regulatory pathway. AL-101 has many of the same properties necessary to replicate the successes I had with the 505(b)2 route for Abraxane at Abraxis and Cynviloq at Igdrasol
Huge Acquisition News Out >> ONCOTELIC TO ACQUIRE LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION.
AGOURA HILLS, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), executed a binding term sheet with Autotelic Inc. to license AL-101 (intranasal apomorphine). Oncotelic intends to develop AL-101 via fast-to-market 505(b)2 regulatory pathway for Parkinson Disease ("PD") and Erectile Dysfunction ("ED"), especially phosphodiesterase 5 ("PDE5") non-responders. AL-101 will also be developed as a new drug against Female Sexual Dysfunction ("FSD"), including Hypoactive Sexual Desire Disorder ("HSDD"). AL-101 has a favorable safety and efficacy profile and is phase 3 ready with six clinical trials completed and over 200 patients (2,200 doses) treated.
"The acquisition of AL-101, expands Oncotelic's product portfolio to the fast to market 505(b)2 regulatory pathway. AL-101 has many of the same properties necessary to replicate the successes I had with the 505(b)2 route for Abraxane at Abraxis and Cynviloq at Igdrasol. I am impressed with its marked improvement on quality of life for PD patients and look forward to working with pts and healthcare professionals in PD." said Dr. Vuong Trieu, CEO and Chairman of Oncotelic.
About Parkinson Disease (PD):
Over 60,000 new patients being diagnosed with PD in the United States and currently there are over 1 million patients in the US and expected to increase to over 1.2 million by 2030. In addition, approximately 10 million suffer from this disease globally. https://www.parkinson.org/Understanding-Parkinsons/Statistics.
On May 2020, KYNMOBI™ (apomorphine HCI) sublingual film developed by Sunovion Pharmaceuticals was approved through the 505(b)2 pathway for acute, intermittent treatment of OFF episodes in patients with Parkinson's disease (PD) dissolves under the tongue. Per Suniovion Pharmaceuticals, KYNMOBI is expected to generate $219 million annually. https://www.pharmaceutical-technology.com/comment/sunovion-pharmaceuticals-kynmobi-parkinsons/
About Erectile Dysfunction (ED)
ED is the most prevalent male sexual disorder globally. The market will continue to grow due to increased vascular disorders followed by the aging population across the world. Furthermore, rising psychological problems, followed by chronic diseases like diabetes, alcohol, and smoking habits are also considered as one of the major driving factors for the growth of the market. Oral PDE5 inhibitors, especially Viagra, Cialis, and Levitra, dominated the market with around US$3.8 billion of revenue in 2020.
The percentages of men affected by ED are as follows: 14.3-70% of men aged 60 years, 6.7-48% of men aged 70 years, and 38% of men aged 80 years (Geerkens MJM et al. (2019). Eur Urol Focus. pii: S2405-4569(19)30079-3). However, with the increasing administration of PDE5 inhibitors in clinical practice, it was found that approximately 30-35% of ED patients are treatment failures (McMahon CN et al. (2006). BMJ, 332: 589-92). AL-101 is designed to target treatment failure ED patients who do not respond to PDE5 inhibitors.
About Female Sexual Dysfunction (FSD):
Female sexual dysfunction is a prevalent problem, afflicting approximately 40% of women and there are few treatment options. FSD is more typical as women age and is a progressive and widespread condition. (Allahdadi, KJ et al. (2009) Cardiovascular & hematological agents in medicinal chemistry, 7(4), 260-269).
HSDD is characterized by a low sexual desire, that causes marked distress or interpersonal difficulty, and is not due to a co-existing medical or psychiatric condition, problems within the relationship or the effects of a medication or other drug substance. HSDD affects approximately 5.8 million U.S. premenopausal women (1 in 10 premenopausal women). Almost 98%, approximately 5.7 million of affected premenopausal women are not on any therapy for HSDD, either due to lack of education or lack of therapies available. One in 10 premenopausal women have low desire with associated distress.
There is no available drug for the treatment of FSD. In June 2019, the U.S. Food and Drug Administration approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women. This is the only available drug treatment. Vyleesi has essentially replaced the only other drug for HSDD - however, it has a long list of drug-drug interactions, including commonly used antidepressants, such as fluoxetine and sertraline. In addition, it has a black box warning regarding its use with alcohol, a combination that has been associated with hypotension and syncopal episodes. Therefore there is an urgent need for effective therapy against FSD and HSDD.
About Oncotelic Therapeutics
Oncotelic Therapeutics, Inc. (f/k/a Mateon Therapeutics, Inc.) ("Oncotelic"), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020.
Oncotelic was created by the 2019 merger with Oncotelic Inc., which became a wholly owned subsidiary of Mateon, thereby creating an immuno-oncology company dedicated to the development of first in class RNA therapeutics, as well as small molecule drugs against cancer and infectious diseases. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-ß RNA therapeutic that exhibited single agent activity in some relapsed/refractory cancer patients in clinical trial settings. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic also has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi 4503). The Company acquired PointR Data Inc. ("PointR") in November 2019. The PointR Acquisition was intended to create a publicly traded artificial intelligence driven immuno-oncology company with a robust pipeline of first in class TGF-ß immunotherapies for late-stage cancers such as gliomas, pancreatic cancer and melanoma.
For more information, please visit www.oncotelic.com.
$OTLC .14 Huge Acquisition News Out >> ONCOTELIC TO ACQUIRE LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION.
AGOURA HILLS, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), executed a binding term sheet with Autotelic Inc. to license AL-101 (intranasal apomorphine). Oncotelic intends to develop AL-101 via fast-to-market 505(b)2 regulatory pathway for Parkinson Disease ("PD") and Erectile Dysfunction ("ED"), especially phosphodiesterase 5 ("PDE5") non-responders. AL-101 will also be developed as a new drug against Female Sexual Dysfunction ("FSD"), including Hypoactive Sexual Desire Disorder ("HSDD"). AL-101 has a favorable safety and efficacy profile and is phase 3 ready with six clinical trials completed and over 200 patients (2,200 doses) treated.
"The acquisition of AL-101, expands Oncotelic's product portfolio to the fast to market 505(b)2 regulatory pathway. AL-101 has many of the same properties necessary to replicate the successes I had with the 505(b)2 route for Abraxane at Abraxis and Cynviloq at Igdrasol. I am impressed with its marked improvement on quality of life for PD patients and look forward to working with pts and healthcare professionals in PD." said Dr. Vuong Trieu, CEO and Chairman of Oncotelic.
About Parkinson Disease (PD):
Over 60,000 new patients being diagnosed with PD in the United States and currently there are over 1 million patients in the US and expected to increase to over 1.2 million by 2030. In addition, approximately 10 million suffer from this disease globally. https://www.parkinson.org/Understanding-Parkinsons/Statistics.
On May 2020, KYNMOBI™ (apomorphine HCI) sublingual film developed by Sunovion Pharmaceuticals was approved through the 505(b)2 pathway for acute, intermittent treatment of OFF episodes in patients with Parkinson's disease (PD) dissolves under the tongue. Per Suniovion Pharmaceuticals, KYNMOBI is expected to generate $219 million annually. https://www.pharmaceutical-technology.com/comment/sunovion-pharmaceuticals-kynmobi-parkinsons/
About Erectile Dysfunction (ED)
ED is the most prevalent male sexual disorder globally. The market will continue to grow due to increased vascular disorders followed by the aging population across the world. Furthermore, rising psychological problems, followed by chronic diseases like diabetes, alcohol, and smoking habits are also considered as one of the major driving factors for the growth of the market. Oral PDE5 inhibitors, especially Viagra, Cialis, and Levitra, dominated the market with around US$3.8 billion of revenue in 2020.
The percentages of men affected by ED are as follows: 14.3-70% of men aged 60 years, 6.7-48% of men aged 70 years, and 38% of men aged 80 years (Geerkens MJM et al. (2019). Eur Urol Focus. pii: S2405-4569(19)30079-3). However, with the increasing administration of PDE5 inhibitors in clinical practice, it was found that approximately 30-35% of ED patients are treatment failures (McMahon CN et al. (2006). BMJ, 332: 589-92). AL-101 is designed to target treatment failure ED patients who do not respond to PDE5 inhibitors.
About Female Sexual Dysfunction (FSD):
Female sexual dysfunction is a prevalent problem, afflicting approximately 40% of women and there are few treatment options. FSD is more typical as women age and is a progressive and widespread condition. (Allahdadi, KJ et al. (2009) Cardiovascular & hematological agents in medicinal chemistry, 7(4), 260-269).
HSDD is characterized by a low sexual desire, that causes marked distress or interpersonal difficulty, and is not due to a co-existing medical or psychiatric condition, problems within the relationship or the effects of a medication or other drug substance. HSDD affects approximately 5.8 million U.S. premenopausal women (1 in 10 premenopausal women). Almost 98%, approximately 5.7 million of affected premenopausal women are not on any therapy for HSDD, either due to lack of education or lack of therapies available. One in 10 premenopausal women have low desire with associated distress.
There is no available drug for the treatment of FSD. In June 2019, the U.S. Food and Drug Administration approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women. This is the only available drug treatment. Vyleesi has essentially replaced the only other drug for HSDD - however, it has a long list of drug-drug interactions, including commonly used antidepressants, such as fluoxetine and sertraline. In addition, it has a black box warning regarding its use with alcohol, a combination that has been associated with hypotension and syncopal episodes. Therefore there is an urgent need for effective therapy against FSD and HSDD.
About Oncotelic Therapeutics
Oncotelic Therapeutics, Inc. (f/k/a Mateon Therapeutics, Inc.) ("Oncotelic"), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020.
Oncotelic was created by the 2019 merger with Oncotelic Inc., which became a wholly owned subsidiary of Mateon, thereby creating an immuno-oncology company dedicated to the development of first in class RNA therapeutics, as well as small molecule drugs against cancer and infectious diseases. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-ß RNA therapeutic that exhibited single agent activity in some relapsed/refractory cancer patients in clinical trial settings. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic also has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi 4503). The Company acquired PointR Data Inc. ("PointR") in November 2019. The PointR Acquisition was intended to create a publicly traded artificial intelligence driven immuno-oncology company with a robust pipeline of first in class TGF-ß immunotherapies for late-stage cancers such as gliomas, pancreatic cancer and melanoma.
For more information, please visit www.oncotelic.com.
$OTLC .14 Huge Acquisition News Out >> ONCOTELIC TO ACQUIRE LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION.
AGOURA HILLS, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), executed a binding term sheet with Autotelic Inc. to license AL-101 (intranasal apomorphine). Oncotelic intends to develop AL-101 via fast-to-market 505(b)2 regulatory pathway for Parkinson Disease ("PD") and Erectile Dysfunction ("ED"), especially phosphodiesterase 5 ("PDE5") non-responders. AL-101 will also be developed as a new drug against Female Sexual Dysfunction ("FSD"), including Hypoactive Sexual Desire Disorder ("HSDD"). AL-101 has a favorable safety and efficacy profile and is phase 3 ready with six clinical trials completed and over 200 patients (2,200 doses) treated.
"The acquisition of AL-101, expands Oncotelic's product portfolio to the fast to market 505(b)2 regulatory pathway. AL-101 has many of the same properties necessary to replicate the successes I had with the 505(b)2 route for Abraxane at Abraxis and Cynviloq at Igdrasol. I am impressed with its marked improvement on quality of life for PD patients and look forward to working with pts and healthcare professionals in PD." said Dr. Vuong Trieu, CEO and Chairman of Oncotelic.
About Parkinson Disease (PD):
Over 60,000 new patients being diagnosed with PD in the United States and currently there are over 1 million patients in the US and expected to increase to over 1.2 million by 2030. In addition, approximately 10 million suffer from this disease globally. https://www.parkinson.org/Understanding-Parkinsons/Statistics.
On May 2020, KYNMOBI™ (apomorphine HCI) sublingual film developed by Sunovion Pharmaceuticals was approved through the 505(b)2 pathway for acute, intermittent treatment of OFF episodes in patients with Parkinson's disease (PD) dissolves under the tongue. Per Suniovion Pharmaceuticals, KYNMOBI is expected to generate $219 million annually. https://www.pharmaceutical-technology.com/comment/sunovion-pharmaceuticals-kynmobi-parkinsons/
About Erectile Dysfunction (ED)
ED is the most prevalent male sexual disorder globally. The market will continue to grow due to increased vascular disorders followed by the aging population across the world. Furthermore, rising psychological problems, followed by chronic diseases like diabetes, alcohol, and smoking habits are also considered as one of the major driving factors for the growth of the market. Oral PDE5 inhibitors, especially Viagra, Cialis, and Levitra, dominated the market with around US$3.8 billion of revenue in 2020.
The percentages of men affected by ED are as follows: 14.3-70% of men aged 60 years, 6.7-48% of men aged 70 years, and 38% of men aged 80 years (Geerkens MJM et al. (2019). Eur Urol Focus. pii: S2405-4569(19)30079-3). However, with the increasing administration of PDE5 inhibitors in clinical practice, it was found that approximately 30-35% of ED patients are treatment failures (McMahon CN et al. (2006). BMJ, 332: 589-92). AL-101 is designed to target treatment failure ED patients who do not respond to PDE5 inhibitors.
About Female Sexual Dysfunction (FSD):
Female sexual dysfunction is a prevalent problem, afflicting approximately 40% of women and there are few treatment options. FSD is more typical as women age and is a progressive and widespread condition. (Allahdadi, KJ et al. (2009) Cardiovascular & hematological agents in medicinal chemistry, 7(4), 260-269).
HSDD is characterized by a low sexual desire, that causes marked distress or interpersonal difficulty, and is not due to a co-existing medical or psychiatric condition, problems within the relationship or the effects of a medication or other drug substance. HSDD affects approximately 5.8 million U.S. premenopausal women (1 in 10 premenopausal women). Almost 98%, approximately 5.7 million of affected premenopausal women are not on any therapy for HSDD, either due to lack of education or lack of therapies available. One in 10 premenopausal women have low desire with associated distress.
There is no available drug for the treatment of FSD. In June 2019, the U.S. Food and Drug Administration approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women. This is the only available drug treatment. Vyleesi has essentially replaced the only other drug for HSDD - however, it has a long list of drug-drug interactions, including commonly used antidepressants, such as fluoxetine and sertraline. In addition, it has a black box warning regarding its use with alcohol, a combination that has been associated with hypotension and syncopal episodes. Therefore there is an urgent need for effective therapy against FSD and HSDD.
About Oncotelic Therapeutics
Oncotelic Therapeutics, Inc. (f/k/a Mateon Therapeutics, Inc.) ("Oncotelic"), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020.
Oncotelic was created by the 2019 merger with Oncotelic Inc., which became a wholly owned subsidiary of Mateon, thereby creating an immuno-oncology company dedicated to the development of first in class RNA therapeutics, as well as small molecule drugs against cancer and infectious diseases. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-ß RNA therapeutic that exhibited single agent activity in some relapsed/refractory cancer patients in clinical trial settings. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic also has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi 4503). The Company acquired PointR Data Inc. ("PointR") in November 2019. The PointR Acquisition was intended to create a publicly traded artificial intelligence driven immuno-oncology company with a robust pipeline of first in class TGF-ß immunotherapies for late-stage cancers such as gliomas, pancreatic cancer and melanoma.
For more information, please visit www.oncotelic.com.
$CBDD .0101 Target $0.26+ >>
Positive Shareholders Equity
$2,000,000
Record Revenues 6 Months
$14.5 million
Record Profits 6 Months
$1.2 million
AUDIT Financials Complete
Releasing Soon
OTCQB Uplift Soon
10 Targeted Acquisitions
European Market
Next $AABB
#CBD #HEMP
$CBDD .0101 Target $0.26+ >>
Positive Shareholders Equity
$2,000,000
Record Revenues 6 Months
$14.5 million
Record Profits 6 Months
$1.2 million
AUDIT Financials Complete
Releasing Soon
OTCQB Uplift Soon
10 Targeted Acquisitions
European Market
Next $AABB
#CBD #HEMP
$CBDD .0101 Huge Acquisition News >> CBD Of Denver Provides Update on Its Growing Acquisition Pipeline
Press Release | 08/31/2021
Denver, Colorado--(Newsfile Corp. - August 31, 2021) - CBD of Denver, Inc. (OTC Pink: CBDD), a full-line CBD and hemp oil company and a producer and distributor of cannabis and CBD products in Switzerland and Europe, is pleased to give an update on its planned acquisitions:
As announced earlier this year, CBD of Denver is planning to make further acquisitions in Switzerland and Europe. The Company has considered approximately 10 potential targets in recent months and began the due diligence process for one in June 2021. Through this process it became apparent that this company's originally communicated figures were incorrect and that it was significantly indebted. Due to these facts, the due diligence process was aborted by CBD of Denver. This target company has since fallen into liquidation and CBD of Denver remains interested in certain assets of the organization, and we are pursuing the liquidation process of this company in order to buy out specific assets if available.
In mid-July 2021, we started the due diligence process for a second company that would be an optimal addition to our group. The current findings confirm this assumption and also the figures of this company correspond to the originally communicated values according to the current state of knowledge. We will complete our due diligence process in the coming weeks and have started the negotiation process with the owner about a possible takeover and the appropriate conditions.
In addition, we currently have two other companies that have been identified as interesting takeover candidates in our general review and we expect to start the due diligence process and an in-depth review of these companies in the coming weeks.
"The cannabis market in Europe is currently in a state of flux," states Marcel Gamma, CEO CBD of Denver. "We see new interesting opportunities and acquisition candidates every week, which we are seriously evaluating and questioning in detail the benefits as a complement to our group. We continue to pursue the strategy of accretive acquisitions to create the highest possible value for the company, our investors and shareholders in the medium and long term."
Follow CBDD on Instagram: @CBDofDenver_Inc @Rockflowr @RockflowrRetail
CBD of Denver, Inc., Rockflowr GmbH and Swiss Industry Ventures AG are now also on LinkedIn.
About CBD of Denver, Inc.
CBD of Denver, Inc. (OTC Pink: CBDD) a full-line CBD and Hemp oil company ("CBDD") and a producer and distributor of Cannabis and CBD products in Switzerland and Europe. CBDD is focused on using equity to acquire profitable Swiss assets at attractive valuations to create value for all our shareholders driven by a passion to improve lives and strengthen communities by unleashing the full potential of cannabis.
Through our brand Rockflowr and BlackPearlCBD we reach our consumers and have built up a strong customer base by focusing on top quality products and meaningful customer relationships.
Black Pearl CBD has 0% THC but is not an Isolate where the THC is stripped from the product rendering it ineffective. We use a proprietary technique adding terpenes as the activation ingredient, resulting in a product that is the finest in the industry and only available at www.cbdofdenver.com.
$CBDD .0101 Huge Acquisition News >> CBD Of Denver Provides Update on Its Growing Acquisition Pipeline
Press Release | 08/31/2021
Denver, Colorado--(Newsfile Corp. - August 31, 2021) - CBD of Denver, Inc. (OTC Pink: CBDD), a full-line CBD and hemp oil company and a producer and distributor of cannabis and CBD products in Switzerland and Europe, is pleased to give an update on its planned acquisitions:
As announced earlier this year, CBD of Denver is planning to make further acquisitions in Switzerland and Europe. The Company has considered approximately 10 potential targets in recent months and began the due diligence process for one in June 2021. Through this process it became apparent that this company's originally communicated figures were incorrect and that it was significantly indebted. Due to these facts, the due diligence process was aborted by CBD of Denver. This target company has since fallen into liquidation and CBD of Denver remains interested in certain assets of the organization, and we are pursuing the liquidation process of this company in order to buy out specific assets if available.
In mid-July 2021, we started the due diligence process for a second company that would be an optimal addition to our group. The current findings confirm this assumption and also the figures of this company correspond to the originally communicated values according to the current state of knowledge. We will complete our due diligence process in the coming weeks and have started the negotiation process with the owner about a possible takeover and the appropriate conditions.
In addition, we currently have two other companies that have been identified as interesting takeover candidates in our general review and we expect to start the due diligence process and an in-depth review of these companies in the coming weeks.
"The cannabis market in Europe is currently in a state of flux," states Marcel Gamma, CEO CBD of Denver. "We see new interesting opportunities and acquisition candidates every week, which we are seriously evaluating and questioning in detail the benefits as a complement to our group. We continue to pursue the strategy of accretive acquisitions to create the highest possible value for the company, our investors and shareholders in the medium and long term."
Follow CBDD on Instagram: @CBDofDenver_Inc @Rockflowr @RockflowrRetail
CBD of Denver, Inc., Rockflowr GmbH and Swiss Industry Ventures AG are now also on LinkedIn.
About CBD of Denver, Inc.
CBD of Denver, Inc. (OTC Pink: CBDD) a full-line CBD and Hemp oil company ("CBDD") and a producer and distributor of Cannabis and CBD products in Switzerland and Europe. CBDD is focused on using equity to acquire profitable Swiss assets at attractive valuations to create value for all our shareholders driven by a passion to improve lives and strengthen communities by unleashing the full potential of cannabis.
Through our brand Rockflowr and BlackPearlCBD we reach our consumers and have built up a strong customer base by focusing on top quality products and meaningful customer relationships.
Black Pearl CBD has 0% THC but is not an Isolate where the THC is stripped from the product rendering it ineffective. We use a proprietary technique adding terpenes as the activation ingredient, resulting in a product that is the finest in the industry and only available at www.cbdofdenver.com.
$CBDD .0101 AUDIT COMPLETE >> CBD of Denver Provides Corporate Update on Its US Audit
Newsfile Corp.
August 30, 2021, 8:52 am
?
Denver, Colorado--(Newsfile Corp. - August 30, 2021) - CBD of Denver, Inc. (OTC Pink: CBDD), a full-line CBD and hemp oil company and a producer and distributor of cannabis and CBD products in Switzerland and Europe, is pleased to give an update on its US audit.
As announced earlier this year, CBD of Denver engaged FRUCI Associates to fulfil the US audit for the Company to become a fully reporting company according to SEC guidelines. The Company has received feedback from FRUCI that the audit team has finished their work and as of now it is - according to FRUCI's lead auditor of CBD of Denver - anticipated that there are no changes on the financials reported. The reports prepared by the audit team will now go through FRUCI quality control, and we expect the final reports distributed very soon.
Additionally, the Company already began preparing its Form-10 filing in parallel together with its corporate counsel to expedite the filing with the SEC as soon as the financial figures are finalized.
"We appreciate the support and patience from our investors and shareholders," states Marcel Gamma, CEO of CBD of Denver. "Although this process has unexpectedly been delayed several times, we are happy that we will hopefully be able to complete this process very soon, confirming the trust and support of our shareholders in CBD of Denver."
Follow CBDD on Instagram: @CBDofDenver_Inc @Rockflowr @RockflowrRetail
CBD of Denver, Inc., Rockflowr GmbH and Swiss Industry Ventures AG are now also on LinkedIn.
About CBD of Denver, Inc.
CBD of Denver, Inc. (OTC Pink: CBDD) a full-line CBD and Hemp oil company ("CBDD") and a producer and distributor of Cannabis and CBD products in Switzerland and Europe. CBDD is focused on using equity to acquire profitable Swiss assets at attractive valuations to create value for all our shareholders driven by a passion to improve lives and strengthen communities by unleashing the full potential of cannabis.
Through our brand Rockflowr and BlackPearlCBD we reach our consumers and have built up a strong customer base by focusing on top quality products and meaningful customer relationships.
Black Pearl CBD has 0% THC but is not an Isolate where the THC is stripped from the product rendering it ineffective. We use a proprietary technique adding terpenes as the activation ingredient, resulting in a product that is the finest in the industry and only available at www.cbdofdenver.com.
$CBDD .0101 AUDIT COMPLETE >> CBD of Denver Provides Corporate Update on Its US Audit
Newsfile Corp.
August 30, 2021, 8:52 am
?
Denver, Colorado--(Newsfile Corp. - August 30, 2021) - CBD of Denver, Inc. (OTC Pink: CBDD), a full-line CBD and hemp oil company and a producer and distributor of cannabis and CBD products in Switzerland and Europe, is pleased to give an update on its US audit.
As announced earlier this year, CBD of Denver engaged FRUCI Associates to fulfil the US audit for the Company to become a fully reporting company according to SEC guidelines. The Company has received feedback from FRUCI that the audit team has finished their work and as of now it is - according to FRUCI's lead auditor of CBD of Denver - anticipated that there are no changes on the financials reported. The reports prepared by the audit team will now go through FRUCI quality control, and we expect the final reports distributed very soon.
Additionally, the Company already began preparing its Form-10 filing in parallel together with its corporate counsel to expedite the filing with the SEC as soon as the financial figures are finalized.
"We appreciate the support and patience from our investors and shareholders," states Marcel Gamma, CEO of CBD of Denver. "Although this process has unexpectedly been delayed several times, we are happy that we will hopefully be able to complete this process very soon, confirming the trust and support of our shareholders in CBD of Denver."
Follow CBDD on Instagram: @CBDofDenver_Inc @Rockflowr @RockflowrRetail
CBD of Denver, Inc., Rockflowr GmbH and Swiss Industry Ventures AG are now also on LinkedIn.
About CBD of Denver, Inc.
CBD of Denver, Inc. (OTC Pink: CBDD) a full-line CBD and Hemp oil company ("CBDD") and a producer and distributor of Cannabis and CBD products in Switzerland and Europe. CBDD is focused on using equity to acquire profitable Swiss assets at attractive valuations to create value for all our shareholders driven by a passion to improve lives and strengthen communities by unleashing the full potential of cannabis.
Through our brand Rockflowr and BlackPearlCBD we reach our consumers and have built up a strong customer base by focusing on top quality products and meaningful customer relationships.
Black Pearl CBD has 0% THC but is not an Isolate where the THC is stripped from the product rendering it ineffective. We use a proprietary technique adding terpenes as the activation ingredient, resulting in a product that is the finest in the industry and only available at www.cbdofdenver.com.
$CBDD .0098 Uplifting, $30m Revs/$2.5m Profits, OTCQB, AUDITED, 10 ACQUISITION TARGETS
$CBDD .0098 Uplifting, $30m Revs/$2.5m Profits, OTCQB, AUDITED, 10 ACQUISITION TARGETS
$CBDD .0098 Huge News Back to Back, AUDIT Complete, 10 Acquisition Targets
$CBDD .0098 Huge News Back to Back, AUDIT Complete, 10 Acquisition Targets
$CBDD .0103 target $0.25+
$CBDD .0103 target $0.25+
Buh bye Felicia
$CBDD .01 Getting pounded, target $0.25+
$CBDD .01 Getting pounded, target $0.25+
As announced earlier this year, CBD of Denver engaged FRUCI Associates to fulfil the US audit for the Company to become a fully reporting company according to SEC guidelines. The Company has received feedback from FRUCI that the audit team has finished their work and as of now it is - according to FRUCI's lead auditor of CBD of Denver - anticipated that there are no changes on the financials reported. The reports prepared by the audit team will now go through FRUCI quality control, and we expect the final reports distributed very soon.
Additionally, the Company already began preparing its Form-10 filing in parallel together with its corporate counsel to expedite the filing with the SEC as soon as the financial figures are finalized.
$CBDD .0099 On Pace for $30m Revs with $2.5m NET PROFIT, ALL AUDITED
$CBDD .0099 On Pace for $30m Revs with $2.5m NET PROFIT, ALL AUDITED
$CBDD .0099 Huge Buys >> CBD of Denver Provides Corporate Update on Its US Audit
Newsfile Corp.
August 30, 2021, 8:52 am
?
Denver, Colorado--(Newsfile Corp. - August 30, 2021) - CBD of Denver, Inc. (OTC Pink: CBDD), a full-line CBD and hemp oil company and a producer and distributor of cannabis and CBD products in Switzerland and Europe, is pleased to give an update on its US audit.
As announced earlier this year, CBD of Denver engaged FRUCI Associates to fulfil the US audit for the Company to become a fully reporting company according to SEC guidelines. The Company has received feedback from FRUCI that the audit team has finished their work and as of now it is - according to FRUCI's lead auditor of CBD of Denver - anticipated that there are no changes on the financials reported. The reports prepared by the audit team will now go through FRUCI quality control, and we expect the final reports distributed very soon.
Additionally, the Company already began preparing its Form-10 filing in parallel together with its corporate counsel to expedite the filing with the SEC as soon as the financial figures are finalized.
"We appreciate the support and patience from our investors and shareholders," states Marcel Gamma, CEO of CBD of Denver. "Although this process has unexpectedly been delayed several times, we are happy that we will hopefully be able to complete this process very soon, confirming the trust and support of our shareholders in CBD of Denver."
Follow CBDD on Instagram: @CBDofDenver_Inc @Rockflowr @RockflowrRetail
CBD of Denver, Inc., Rockflowr GmbH and Swiss Industry Ventures AG are now also on LinkedIn.
About CBD of Denver, Inc.
CBD of Denver, Inc. (OTC Pink: CBDD) a full-line CBD and Hemp oil company ("CBDD") and a producer and distributor of Cannabis and CBD products in Switzerland and Europe. CBDD is focused on using equity to acquire profitable Swiss assets at attractive valuations to create value for all our shareholders driven by a passion to improve lives and strengthen communities by unleashing the full potential of cannabis.
Through our brand Rockflowr and BlackPearlCBD we reach our consumers and have built up a strong customer base by focusing on top quality products and meaningful customer relationships.
Black Pearl CBD has 0% THC but is not an Isolate where the THC is stripped from the product rendering it ineffective. We use a proprietary technique adding terpenes as the activation ingredient, resulting in a product that is the finest in the industry and only available at www.cbdofdenver.com.
Information contained herein includes forward-looking statements. These statements relate to future events or future financial performance, involving known and unknown risks and you should not place undue reliance on these statements. Any forward-looking statement reflects our current views with respect to future events. We assume no obligation publicly about update or revise these forward-looking statements for any reason.
Contacts:
Marcel Gamma
marcel@cbdofdenver.com
Todd McKnight
RedChip Companies
1-800-733-2447
todd@redchip.com
?
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/94861
$CBDD .0099 Huge Buys >> CBD of Denver Provides Corporate Update on Its US Audit
Newsfile Corp.
August 30, 2021, 8:52 am
?
Denver, Colorado--(Newsfile Corp. - August 30, 2021) - CBD of Denver, Inc. (OTC Pink: CBDD), a full-line CBD and hemp oil company and a producer and distributor of cannabis and CBD products in Switzerland and Europe, is pleased to give an update on its US audit.
As announced earlier this year, CBD of Denver engaged FRUCI Associates to fulfil the US audit for the Company to become a fully reporting company according to SEC guidelines. The Company has received feedback from FRUCI that the audit team has finished their work and as of now it is - according to FRUCI's lead auditor of CBD of Denver - anticipated that there are no changes on the financials reported. The reports prepared by the audit team will now go through FRUCI quality control, and we expect the final reports distributed very soon.
Additionally, the Company already began preparing its Form-10 filing in parallel together with its corporate counsel to expedite the filing with the SEC as soon as the financial figures are finalized.
"We appreciate the support and patience from our investors and shareholders," states Marcel Gamma, CEO of CBD of Denver. "Although this process has unexpectedly been delayed several times, we are happy that we will hopefully be able to complete this process very soon, confirming the trust and support of our shareholders in CBD of Denver."
Follow CBDD on Instagram: @CBDofDenver_Inc @Rockflowr @RockflowrRetail
CBD of Denver, Inc., Rockflowr GmbH and Swiss Industry Ventures AG are now also on LinkedIn.
About CBD of Denver, Inc.
CBD of Denver, Inc. (OTC Pink: CBDD) a full-line CBD and Hemp oil company ("CBDD") and a producer and distributor of Cannabis and CBD products in Switzerland and Europe. CBDD is focused on using equity to acquire profitable Swiss assets at attractive valuations to create value for all our shareholders driven by a passion to improve lives and strengthen communities by unleashing the full potential of cannabis.
Through our brand Rockflowr and BlackPearlCBD we reach our consumers and have built up a strong customer base by focusing on top quality products and meaningful customer relationships.
Black Pearl CBD has 0% THC but is not an Isolate where the THC is stripped from the product rendering it ineffective. We use a proprietary technique adding terpenes as the activation ingredient, resulting in a product that is the finest in the industry and only available at www.cbdofdenver.com.
Information contained herein includes forward-looking statements. These statements relate to future events or future financial performance, involving known and unknown risks and you should not place undue reliance on these statements. Any forward-looking statement reflects our current views with respect to future events. We assume no obligation publicly about update or revise these forward-looking statements for any reason.
Contacts:
Marcel Gamma
marcel@cbdofdenver.com
Todd McKnight
RedChip Companies
1-800-733-2447
todd@redchip.com
?
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/94861
CBD of Denver Provides Corporate Update on Its US Audit
Newsfile Corp.
August 30, 2021, 8:52 am
?
Denver, Colorado--(Newsfile Corp. - August 30, 2021) - CBD of Denver, Inc. (OTC Pink: CBDD), a full-line CBD and hemp oil company and a producer and distributor of cannabis and CBD products in Switzerland and Europe, is pleased to give an update on its US audit.
As announced earlier this year, CBD of Denver engaged FRUCI Associates to fulfil the US audit for the Company to become a fully reporting company according to SEC guidelines. The Company has received feedback from FRUCI that the audit team has finished their work and as of now it is - according to FRUCI's lead auditor of CBD of Denver - anticipated that there are no changes on the financials reported. The reports prepared by the audit team will now go through FRUCI quality control, and we expect the final reports distributed very soon.
Additionally, the Company already began preparing its Form-10 filing in parallel together with its corporate counsel to expedite the filing with the SEC as soon as the financial figures are finalized.
"We appreciate the support and patience from our investors and shareholders," states Marcel Gamma, CEO of CBD of Denver. "Although this process has unexpectedly been delayed several times, we are happy that we will hopefully be able to complete this process very soon, confirming the trust and support of our shareholders in CBD of Denver."
Follow CBDD on Instagram: @CBDofDenver_Inc @Rockflowr @RockflowrRetail
CBD of Denver, Inc., Rockflowr GmbH and Swiss Industry Ventures AG are now also on LinkedIn.
About CBD of Denver, Inc.
CBD of Denver, Inc. (OTC Pink: CBDD) a full-line CBD and Hemp oil company ("CBDD") and a producer and distributor of Cannabis and CBD products in Switzerland and Europe. CBDD is focused on using equity to acquire profitable Swiss assets at attractive valuations to create value for all our shareholders driven by a passion to improve lives and strengthen communities by unleashing the full potential of cannabis.
Through our brand Rockflowr and BlackPearlCBD we reach our consumers and have built up a strong customer base by focusing on top quality products and meaningful customer relationships.
Black Pearl CBD has 0% THC but is not an Isolate where the THC is stripped from the product rendering it ineffective. We use a proprietary technique adding terpenes as the activation ingredient, resulting in a product that is the finest in the industry and only available at www.cbdofdenver.com.
Information contained herein includes forward-looking statements. These statements relate to future events or future financial performance, involving known and unknown risks and you should not place undue reliance on these statements. Any forward-looking statement reflects our current views with respect to future events. We assume no obligation publicly about update or revise these forward-looking statements for any reason.
Contacts:
Marcel Gamma
marcel@cbdofdenver.com
Todd McKnight
RedChip Companies
1-800-733-2447
todd@redchip.com
?
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/94861
$CBDD .0098 Here comes the Penny Break
$CBDD .0098 Here comes the Penny Break
You're a moron.